Xeris Biopharma Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview

Xeris Biopharma Holdings

04/03/2025 14:17

Xeris Biopharma Holdings Inc XERS.OQ XERS.O is expected to show a rise in quarterly revenue when it reports  results on March 6 for the period ending December 31 2024

The Chicago Illinois-based  company is expected to report a 30.9% increase in revenue to $58.104 million from $44.39 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Xeris Biopharma Holdings Inc is for a loss of 6 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $5.00​, above​ its last closing price of $3.69. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.10
-0.09
-0.11
Missed
-22.2
Jun. 30 2024
-0.11
-0.11
-0.10
Beat
6.3
Mar. 31 2024
-0.12
-0.12
-0.14
Missed
-20​
Dec. 31 2023
-0.10
-0.10
-0.10
Met
-2
​​Sep. 30 2023
-0.12
-0.12
-0.09
Beat
22.4
Jun. 30 2023
-0.13
-0.13
-0.14
Missed
-9.8​
Mar. 31 2023
-0.17
-0.17
-0.12
Beat
28.4
Dec. 31 2022
-0.16
-0.16
-0.10
Beat
36.5

This summary was machine generated March 4 at 14:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)